ICYMI: The latest as America’s biopharmaceutical companies work to beat COVID-19
By Andrew Powaleny | August 4, 2020
America’s biopharmaceutical companies are working around the clock to defeat COVID-19, a disease caused by a novel strain of the coronavirus. The biopharmaceutical industry continues to make...
Read More
Executive order threatens R&D when we need it most to fight COVID-19
By Nicole Longo | July 30, 2020
In case you missed it, President Trump recently signed executive orders that would implement sweeping changes to the biopharmaceutical industry. While his intention may have been to help Americans...
Read More
The continued imperative to protect U.S. innovation worldwide
By Chris Moore | April 29, 2020
The COVID-19 pandemic is further demonstrating that the world needs biopharmaceutical innovation to address pressing global health challenges – both now and in the future. PhRMA members are...
Read More
Three reasons the Administration should abandon its International Pricing Index proposal
By Nicole Longo | January 31, 2020
According to the Council of Economic Advisers, “Heavy-handed government intervention may reduce drug prices in the short term, but these savings are not worth the long-term cost of American...
Read More
Guest Post: Following my stroke, having access to ground-breaking medical innovation has never been more important
By Guest Contributor | September 4, 2019
Conversations and healthy debate about issues facing our industry and the health care system are critical to addressing some of today’s challenges and opportunities. The Catalyst welcomes guest...
Read More
Setting the record straight on international reference pricing
By Kevin Haninger | July 16, 2019
There’s been a lot of talk in Washington about how to help patients better access and afford their medicines. These are important discussions that will hopefully result in real affordability...
Read More
By the numbers: A look at the Part B International Pricing Index Model
By Nicole Longo | June 6, 2019
Mounting research continues to point to how international reference pricing schemes, like the Department of Health and Human Services’ (HHS) International Pricing Index (IPI) Model, could result...
Read More
Fact Check: How the Part B International Pricing Index Model replaces market competition with government-set prices
By Nicole Longo | May 3, 2019
One of the most common misconceptions about the administration’s proposed Part B International Pricing Index (IPI) Model is that it would improve competition in Medicare. However, mounting...
Read More
Fact Check: How the Part B International Pricing Index model threatens patient access
By Nicole Longo | March 29, 2019
Since the Department of Health and Human Services (HHS) released the Part B International Pricing Index (IPI) model late last year, there have been a number of inaccurate claims floating around...
Read More
Special 301 submission calls for a level playing field for American innovators
By Megan Van Etten | March 13, 2019
The Office of the U.S. Trade Representative (USTR)’s 2019 Special 301 Report – scheduled to be released this spring – brings critical attention to overseas intellectual property (IP) and market...
Read More
Medicare Monday (100)
340B Spotlight (43)
Cost & Consequence (0)
